This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Juno Therapeutics Inc.
Drug Names(s): BIIB14, BIIB014, V2006
Description: BIIB14 blocks the neuromodulatory adenosine 2a receptor that, in the brain, is almost exclusively found on dopamine D2 receptor–bearing striatopallidal neurons. These neurons secrete the neurotransmitter GABA and have an inhibitory effect. It is thought that the reduction in dopamine seen in Parkinson's disease leads to overactivity in these neurons. The adenosine 2a receptor blockade enhances the effects of dopamine on these neurons, thereby suppressing their inhibitory output.
Deal Structure: V2006 was originally discovered by Vernalis.
Vernalis and Biogen
In June 2004, Vernalis signed a collaboration agreement with Biogen Idec for V2006 (BIIB14). Biogen Idec funds all development of the compound, and Vernalis is to receive milestones and double digit royalties. There is an option for Vernalis to co-promote BIIB14 in the US. Vernalis regained the programme in April 2011.
Vernalis and Redox
In October 2014, Vernalis licensed worldwide rights for vipadenant to RedoxTherapies. The detailed financial terms of the Licence Agreement with Redox are not disclosed, but Vernalis can earn milestones and royalties on successful clinical, regulatory and commercial advancement.
Juno and Redox
In July 2016, Juno Therapeutics announced that it has acquired RedoxTherapies. The acquisition provides Juno with an exclusive license to vipadenant. In addition to vipadenant, with the transaction Juno has acquired proprietary know-how and...See full deal structure in Biomedtracker
Partners: Vernalis Group plc
Additional information available to subscribers only: